[Differentiation and a change in the sensitivity to antibrain serum of circulating colony-forming units under the action of thymic factors].
Popov. B V BV; Lesnikov. V A VA; Isaeva. E N EN
Key Findings
- Thymalin raised granulocytopoietic activity of circulating colony‑forming units (CFU)
- Thymalin reduced CFU sensitivity to rabbit anti‑mouse brain serum (RAMBS)
- CFU differentiation and erythroid activity were largely unchanged
Practical Outcomes
- The findings hint that thymalin might influence immune cell production, but the study is in animals and uses a complex serum assay, so there’s no clear, safe dosage or protocol for humans. Biohackers should treat this as early‑stage evidence and wait for human data before trying thymalin for health benefits.
Summary
In mice, the thymus extract called thymalin boosted the production of certain white‑blood‑cell precursors and made them less sensitive to a specific anti‑brain serum, but it didn’t change how these cells mature.
Abstract
The rabbit anti-mouse brain serum (RAMBS) that interacts with SC-1 marked cells, rather than with thymocytes and bone marrow cells, inhibits most of the blood and bone marrow colony-forming unit (CFU) population. A commercial thymus preparation thymalin increases the granulocytopoietic activity of the circulating CFU and decreases their sensitivity to RAMBS in thymectomized and normal animals. Differentiation of circulating CFU remains unchanged in thymalin-treated mice after RAMBS administration, while CFU erythroid activity of nontreated animals is lowered. The revealed changes in the CFU differentiation and sensitivity to RAMBS confirm the assumption that SC-1 antigen may mark Thy-1 lymphocytes of their microenvironment, rather than CFU.
Study Information
pubmed
1988